Breaking News Instant updates and real-time market news.

FC

Franklin Covey

$36.74 /

-0.015 (-0.04%)

08:15
08/19/21
08/19
08:15
08/19/21
08:15

Franklin Covey price target raised to $45 from $40 at Barrington

Barrington analyst Alexander Paris raised the firm's price target on Franklin Covey to $45 from $40 and keeps an Outperform rating on the shares after hosting meetings with management. The analyst expects management to increase and provide more detail on its outlook for future years when it reports year-end results in early November. He continues to expect Franklin Covey to achieve accelerating revenue growth, as its legacy business continues to run off and subscription revenue increases as a percentage of the total.

FC Franklin Covey
$36.74 /

-0.015 (-0.04%)

07/02/21 Roth Capital
Franklin Covey price target raised to $45 from $36 at Roth Capital
07/01/21 Barrington
Franklin Covey price target raised to $40 from $35 at Barrington
04/05/21 Barrington
Franklin Covey price target raised to $35 from $30 at Barrington
04/05/21 Roth Capital
Franklin Covey price target raised to $36 from $30 at Roth Capital

TODAY'S FREE FLY STORIES

Initiation
Carsales.Com reinstated with a Neutral at Goldman Sachs » 09:05
10/16/21
10/16
09:05
10/16/21
09:05
CSSSF

Carsales.Com

$14.94 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Kane Hannan reinstated coverage of Carsales.Com with a Neutral rating and A$26.40 price target following the company's acquisition of a 49% stake of Trader Interactive. The analyst sees a meaningful opportunity within Carsales.Com's select digital marketplace strategy, but says this will take time to monetize.

Periodicals
BAT hardly flaming out, new products should help boost stock, Barron's says » 08:30
10/16/21
10/16
08:30
10/16/21
08:30
BTI

British American Tobacco

$36.10 /

+0.035 (+0.10%)

Cigarette maker British…

Cigarette maker British American Tobacco has been under pressure as effective public health campaigns led to restrictions on smoking in public places, and changed the way its products are marketed, Rupert Steiner writes in this week's edition of Barron's. But the maker of Lucky Strike and Newport in 2020 invested EUR 430M in new products that included e-cigarette Vuse, glo tobacco-heated products, and Velo nicotine pouches, the author notes. While noncombustible products-those that don't involve burning tobacco-account for just 12% of overall revenue, new Chief Executive Officer Jack Bowles says BAT's new products are set to soar this year. Reference Link

ShowHide Related Items >><<
BTI British American Tobacco
$36.10 /

+0.035 (+0.10%)

BTI British American Tobacco
$36.10 /

+0.035 (+0.10%)

09/30/21 Stifel
Stifel surprised and 'disappointed' by ITC banning IQOS importation
09/30/21 BofA
Altria, Philip Morris still well positioned despite IQOS 'setback,' says BofA
09/28/21 UBS
British American Tobacco price target lowered to 3,500 GBp at UBS
09/13/21 Stifel
Altria could trade down on news of Democrats' proposal, says Stifel
BTI British American Tobacco
$36.10 /

+0.035 (+0.10%)

BTI British American Tobacco
$36.10 /

+0.035 (+0.10%)

BTI British American Tobacco
$36.10 /

+0.035 (+0.10%)

Periodicals
Spinoff could unlock value in Dell stock, Barron's says » 08:27
10/16/21
10/16
08:27
10/16/21
08:27
DELL

Dell Technologies

$107.69 /

+1.71 (+1.61%)

, VMW

VMware

$156.39 /

+4.03 (+2.65%)

Many investors have paid…

Many investors have paid Dell Technologies little attention in recent years and it might be time to take a fresh look, Andrew Bary writes in this week's edition of Barron's. Dell Technologies (DELL) is about to become much more attractive to investors as it prepares to spin off its valuable stake in software maker VMware (VMW) in early November, the author contends, arguing that Dell will emerge with a solid balance sheet and simpler structure. Reference Link

ShowHide Related Items >><<
VMW VMware
$156.39 /

+4.03 (+2.65%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

09/24/21 Morgan Stanley
Dell Technologies price target lowered to $126 from $133 at Morgan Stanley
09/24/21 Citi
Dell trading at 20%-25% discount to peers, says Citi
09/17/21 Citi
Dell Technologies resumed with a Buy at Citi
09/17/21 Morgan Stanley
Morgan Stanley would be buyers of Dell Technologies ahead of analyst day
VMW VMware
$156.39 /

+4.03 (+2.65%)

09/02/21 Citi
VMware price target raised to $190 from $178 at Citi
08/27/21 Monness Crespi
VMware quarter 'subdued' in 'upbeat' earnings season, says Monness Crespi
VMW VMware
$156.39 /

+4.03 (+2.65%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

VMW VMware
$156.39 /

+4.03 (+2.65%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

VMW VMware
$156.39 /

+4.03 (+2.65%)

DELL Dell Technologies
$107.69 /

+1.71 (+1.61%)

Periodicals
Chevron, Citigroup among stocks to beat inflation, Barron's says » 08:25
10/16/21
10/16
08:25
10/16/21
08:25
CVX

Chevron

$109.59 /

+0.78 (+0.72%)

, C

Citi

$72.29 /

+1.46 (+2.06%)

, NEM

Newmont

$57.02 /

-0.77 (-1.33%)

Inflation is proving to…

Inflation is proving to be more enduring than passing, leaving investors on the hunt for reliable sources of income, Carleton English writes in this week's edition of Barron's. Basically, investors are on the hunt for a dividend unicorn: companies that offer higher-than-average yields for their sector and that have a history of increasing that payout. And to avoid getting caught in a value trap, investors will want to look for names that demonstrate the sustainability of their growing dividend by having a lower payout ratio than the sector average and not being overly leveraged, the author contends. Chevron (CVX) is one stock that meets many of those four criteria, offering a yield of 5% after raising its dividend by 4% earlier this year, the publication points out, adding that Citigroup (C) stock also works as a dividend play as well as a comeback story. While the cases for Chevron and Citigroup are pretty straightforward, there's a play in the materials space that looks interesting and meets the criteria: Newmont (NEM). Reference Link

ShowHide Related Items >><<
NEM Newmont
$57.02 /

-0.77 (-1.33%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

C Citi
$72.29 /

+1.46 (+2.06%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

10/07/21 Truist
Chevron price target raised to $150 from $145 at Truist
09/15/21
Fly Intel: Top five analyst downgrades
09/15/21 Citi
Chevron energy transition update as expected, says Citi
09/15/21 JPMorgan
Chevron downgraded to Neutral on higher spending at JPMorgan
C Citi
$72.29 /

+1.46 (+2.06%)

10/15/21 BMO Capital
Citi price target raised to $86 from $84 at BMO Capital
10/11/21 Jefferies
Citi price target raised to $87 from $81 at Jefferies
09/29/21 Oppenheimer
Morgan Stanley downgraded to Perform at Oppenheimer on valuation
07/15/21 Piper Sandler
Citi price target lowered to $91 from $95 at Piper Sandler
NEM Newmont
$57.02 /

-0.77 (-1.33%)

10/12/21 Credit Suisse
Credit Suisse sees 're-rating potential' for gold valuation multiples
09/24/21 KeyBanc
Newmont initiated with a Sector Weight at KeyBanc
09/10/21 National Bank
Newmont price target lowered to C$99 from C$104 at National Bank
07/26/21 TD Securities
Newmont downgraded to Hold from Buy at TD Securities
NEM Newmont
$57.02 /

-0.77 (-1.33%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

C Citi
$72.29 /

+1.46 (+2.06%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

C Citi
$72.29 /

+1.46 (+2.06%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

C Citi
$72.29 /

+1.46 (+2.06%)

NEM Newmont
$57.02 /

-0.77 (-1.33%)

CVX Chevron
$109.59 /

+0.78 (+0.72%)

C Citi
$72.29 /

+1.46 (+2.06%)

Periodicals
MeiraGTx stock could more than double, Barron's says » 08:19
10/16/21
10/16
08:19
10/16/21
08:19
MGTX

MeiraGTx

$14.29 /

+0.76 (+5.62%)

, NVS

Novartis

$83.34 /

+0.715 (+0.87%)

, RHHBY

Roche

$48.92 /

+0.67 (+1.39%)

Since the excitement of…

Since the excitement of multibillion-dollar acquisitions of gene-therapy companies by Novartis (NVS) and Roche (RHHBY) a few years ago, many gene-therapy stocks have sunk to small-cap valuations, Bill Alpert writes in this week's edition of Barron's. Among them is MeiraGTx (MGTX), shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million, the author notes, adding that it could be an opportunity for investors. MeiraGTx will present its gene-regulating "switches" at next week's conference of the European Society of Gene and Cell Therapy, and to Wall Street investors in mid-December. Next year, Meira hopes to start human trials on pills containing small-molecule drugs that could tightly regulate the output of previously transferred genes, the publication says. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$48.92 /

+0.67 (+1.39%)

NVS Novartis
$83.34 /

+0.715 (+0.87%)

MGTX MeiraGTx
$14.29 /

+0.76 (+5.62%)

MGTX MeiraGTx
$14.29 /

+0.76 (+5.62%)

08/11/21 Piper Sandler
Piper remains buyer of MeiraGTx 'into $40 range' after 'quiet' Q2
07/09/21 Chardan
MeiraGTx coverage transferred at Chardan
04/28/21 Piper Sandler
MeiraGTx should be bought into the $40 range, says Piper Sandler
02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
NVS Novartis
$83.34 /

+0.715 (+0.87%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$48.92 /

+0.67 (+1.39%)

10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
RHHBY Roche
$48.92 /

+0.67 (+1.39%)

NVS Novartis
$83.34 /

+0.715 (+0.87%)

MGTX MeiraGTx
$14.29 /

+0.76 (+5.62%)

  • 19
    Nov
RHHBY Roche
$48.92 /

+0.67 (+1.39%)

NVS Novartis
$83.34 /

+0.715 (+0.87%)

RHHBY Roche
$48.92 /

+0.67 (+1.39%)

NVS Novartis
$83.34 /

+0.715 (+0.87%)

NVS Novartis
$83.34 /

+0.715 (+0.87%)

On The Fly
Opening Day: GitLab jumps in Nasdaq debut as IHS opens well below IPO price » 08:12
10/16/21
10/16
08:12
10/16/21
08:12
MSFT

Microsoft

$304.19 /

+1.565 (+0.52%)

, FNA

Paragon 28

$18.70 /

-0.61 (-3.16%)

, INKT

MiNK Therapeutics

$11.94 /

-0.06 (-0.50%)

, GTLB

GitLab

$115.00 /

+11.13 (+10.72%)

, IHS

IHS Holding

$16.66 /

-0.3 (-1.77%)

, LUCD

Lucid Diagnostics

$9.37 /

-2.82 (-23.13%)

, CLST

Catalyst Bancorp

$13.81 /

+0.07 (+0.51%)

, HCTI

Healthcare Triangle

$3.42 /

-0.09 (-2.56%)

, AVDX

AvidXchange

$23.42 /

-0.94 (-3.86%)

, HLTH

Cue Health

$10.69 /

+0.18 (+1.71%)

, CWAN

Clearwater Analytics

$24.41 /

+0.04 (+0.16%)

, ARBK

Argo Blockchain

$16.94 /

+1.39 (+8.94%)

, BRLT

Brilliant Earth

$13.66 /

+0.775 (+6.01%)

, SOVO

Sovos Brands

$14.20 /

+0.2 (+1.43%)

, STER

Sterling Check

$25.49 /

+0.49 (+1.96%)

, THRN

Thorne HealthTech

$7.97 /

+0.02 (+0.25%)

, ESMT

EngageSmart

$32.20 /

+0.14 (+0.44%)

, RELY

Remitly Global

$40.06 /

+1.7 (+4.43%)

, WRBY

Warby Parker

$54.34 /

+0.455 (+0.84%)

, JUNS

Jupiter Neurosciences

/

+

, MDXH

MDxHealth

/

+

, LVLU

Lulu’s Fashion Lounge

/

+

, QNIU

Qiniu

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, PTLO

Portillo’s

/

+

, AMZN

Amazon.com

$3,409.08 /

+110.11 (+3.34%)

, F

Ford

$15.70 /

+0.245 (+1.59%)

, WCGC

WCG Clinical

/

+

Shares of GitLab jumped…

ShowHide Related Items >><<
WRBY Warby Parker
$54.34 /

+0.455 (+0.84%)

MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

HLTH Cue Health
$10.69 /

+0.18 (+1.71%)

F Ford
$15.70 /

+0.245 (+1.59%)

ESMT EngageSmart
$32.20 /

+0.14 (+0.44%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

10/06/21 Morgan Stanley
CIO survey shows Microsoft 'further solidifying leadership,' says Morgan Stanley
09/24/21 Oppenheimer
Opco downgrades Cloudflare amid competition from Amazon, Microsoft
09/24/21 Piper Sandler
Salesforce upgraded to Overweight from Neutral at Piper Sandler
09/17/21 Tigress Financial
Microsoft price target raised to $366 from $303 at Tigress Financial
FNA Paragon 28
$18.70 /

-0.61 (-3.16%)

INKT MiNK Therapeutics
$11.94 /

-0.06 (-0.50%)

GTLB GitLab
$115.00 /

+11.13 (+10.72%)

IHS IHS Holding
$16.66 /

-0.3 (-1.77%)

LUCD Lucid Diagnostics
$9.37 /

-2.82 (-23.13%)

CLST Catalyst Bancorp
$13.81 /

+0.07 (+0.51%)

HCTI Healthcare Triangle
$3.42 /

-0.09 (-2.56%)

AVDX AvidXchange
$23.42 /

-0.94 (-3.86%)

HLTH Cue Health
$10.69 /

+0.18 (+1.71%)

CWAN Clearwater Analytics
$24.41 /

+0.04 (+0.16%)

ARBK Argo Blockchain
$16.94 /

+1.39 (+8.94%)

BRLT Brilliant Earth
$13.66 /

+0.775 (+6.01%)

SOVO Sovos Brands
$14.20 /

+0.2 (+1.43%)

STER Sterling Check
$25.49 /

+0.49 (+1.96%)

THRN Thorne HealthTech
$7.97 /

+0.02 (+0.25%)

ESMT EngageSmart
$32.20 /

+0.14 (+0.44%)

RELY Remitly Global
$40.06 /

+1.7 (+4.43%)

WRBY Warby Parker
$54.34 /

+0.455 (+0.84%)

10/04/21
Fly Intel: Top five analyst initiations
10/04/21 Loop Capital
Warby Parker initiated with a Hold at Loop Capital
JUNS Jupiter Neurosciences
/

+

MDXH MDxHealth
/

+

LVLU Lulu’s Fashion Lounge
/

+

QNIU Qiniu
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

PTLO Portillo’s
/

+

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

10/13/21 Baird
Amazon.com weakness would be a buying opportunity, says Baird
10/12/21 JPMorgan
JPMorgan says Alphabet 'clearly the most liked' mega-cap internet stock
10/11/21 Loop Capital
Bed Bath & Beyond price target lowered to $14 from $18 at Loop Capital
10/07/21 Stephens
Comcast-branded Smart TV Launch in U.S. 'likely imminent,' says Stephens
F Ford
$15.70 /

+0.245 (+1.59%)

10/04/21 RBC Capital
Lordstown Motors price target raised to $5 from $1 at RBC Capital
09/28/21 Morgan Stanley
Morgan Stanley says Ford 'late to party' on BEVs, but 'turning music up loud'
09/26/21 Goldman Sachs
Lordstown Motors downgraded to Sell from Neutral at Goldman Sachs
09/08/21 Benchmark
Worst of chip shortage could be over for Ford, says Benchmark
WCGC WCG Clinical
/

+

MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

F Ford
$15.70 /

+0.245 (+1.59%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

  • 21
    Oct
  • 13
    Oct
  • 15
    Oct
  • 15
    Oct
  • 14
    Oct
  • 14
    Oct
  • 14
    Oct
  • 13
    Oct
  • 24
    Sep
  • 23
    Sep
  • 23
    Sep
  • 23
    Sep
  • 23
    Sep
  • 23
    Sep
  • 24
    Sep
  • 23
    Sep
  • 23
    Sep
  • 29
    Sep
  • 05
    Aug
MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

F Ford
$15.70 /

+0.245 (+1.59%)

CWAN Clearwater Analytics
$24.41 /

+0.04 (+0.16%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

WRBY Warby Parker
$54.34 /

+0.455 (+0.84%)

MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

LUCD Lucid Diagnostics
$9.37 /

-2.82 (-23.13%)

HLTH Cue Health
$10.69 /

+0.18 (+1.71%)

GTLB GitLab
$115.00 /

+11.13 (+10.72%)

F Ford
$15.70 /

+0.245 (+1.59%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

MSFT Microsoft
$304.19 /

+1.565 (+0.52%)

HLTH Cue Health
$10.69 /

+0.18 (+1.71%)

F Ford
$15.70 /

+0.245 (+1.59%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

Syndicate
Great Panther Mining re-establishes $25M at-the-market facility » 18:26
10/15/21
10/15
18:26
10/15/21
18:26
GPL

Great Panther Mining

/

+

Great Panther Mining…

Great Panther Mining announces that it has entered into an At-the-Market Offering Agreement of up to $25M dated October 15, with H.C. Wainwright & Co.. This offering replaces the company's prior $25M At-the-Market offering, which expired on August 3.

ShowHide Related Items >><<
GPL Great Panther Mining
/

+

GPL Great Panther Mining
/

+

10/09/21 Cantor Fitzgerald
Great Panther Mining downgraded to Hold from Buy at Cantor Fitzgerald
10/08/21 Alliance Global Partners
Great Panther price target lowered to 70c from $1.20 at Alliance Global
10/29/20 Roth Capital
Great Panther Mining resumed with a Buy at Roth Capital
Hot Stocks
TherapeuticsMD names Mark Glickman as Chief Business Officer » 17:34
10/15/21
10/15
17:34
10/15/21
17:34
TXMD

TherapeuticsMD

/

+

TherapeuticsMD announced…

TherapeuticsMD announced the appointment of Mark Glickman as the company's Chief Business Officer. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles.

ShowHide Related Items >><<
TXMD TherapeuticsMD
/

+

TXMD TherapeuticsMD
/

+

08/05/21 Cowen
TherapeuticsMD price target lowered to $5 from $9 at Cowen
01/28/21 H.C. Wainwright
TherapeuticsMD price target lowered to $4 from $5 at H.C. Wainwright
TXMD TherapeuticsMD
/

+

  • 11
    Feb
  • 10
    Nov
Periodicals
Stellantis to turn Windsor plant into one-shift operation, Automotive News says » 17:28
10/15/21
10/15
17:28
10/15/21
17:28
STLA

Stellantis

$19.98 /

+0.145 (+0.73%)

Stellantis intends to…

Stellantis intends to convert its Windsor, Ontario minivan factory into a one-shift operation starting in the spring of 2022, Automotive News Canada's Greg Layson reports. The car marker did not say when one of the two remaining shifts will be cut, but it did blame the ongoing chip shortage and COVID-19 pandemic for the change, the author notes. Reference Link

ShowHide Related Items >><<
STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

09/07/21 KeyBanc
Jeep micro site on Amazon points to auto sales moving online, says KeyBanc
09/03/21 Deutsche Bank
Stellantis deal 'significant opportunity' for Open Lending, says Deutsche Bank
09/02/21 DA Davidson
DA Davidson says Stellantis opportunity for Open Lending not 'fait accompli'
09/02/21 Raymond James
Raymond James says buy Open Lending aggressively after Stellantis deal
STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

Syndicate
Renovacor files to sell 12.67M shares of common stock for holders  17:15
10/15/21
10/15
17:15
10/15/21
17:15
RCOR

Renovacor

$8.15 /

+0.36 (+4.62%)

 
ShowHide Related Items >><<
RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/01/21 Chardan
Renovacor initiated with a Buy, $20 target at Chardan
10/01/21 Chardan
Renovacor initiated with a Buy at Chardan
Syndicate
Renovacor files to sell 8.53M shares of common stock  17:15
10/15/21
10/15
17:15
10/15/21
17:15
RCOR

Renovacor

$8.15 /

+0.36 (+4.62%)

 
ShowHide Related Items >><<
RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/01/21 Chardan
Renovacor initiated with a Buy, $20 target at Chardan
10/01/21 Chardan
Renovacor initiated with a Buy at Chardan
Hot Stocks
Revance gets CRL from FDA, says it is unable to approve DaxibotulinumtoxinA BLA » 17:13
10/15/21
10/15
17:13
10/15/21
17:13
RVNC

Revance

$22.72 /

+0.24 (+1.07%)

Revance announced that…

Revance announced that the FDA has issued a complete response letter, or CRL, regarding the biologics license application, or BLA, for DaxibotulinumtoxinA for injection, for the treatment of moderate to severe glabellar lines. In a communication received on October 15, the FDA has determined it is unable to approve the BLA in its present form, and indicated that there are deficiencies related to the FDA's onsite inspection at Revance's manufacturing facility. Revance plans to request a Type A meeting with the FDA as soon as possible to address the deficiencies raised. No other deficiencies were identified in the CRL.

ShowHide Related Items >><<
RVNC Revance
$22.72 /

+0.24 (+1.07%)

RVNC Revance
$22.72 /

+0.24 (+1.07%)

10/13/21 Mizuho
Revance issues in Form 483 'must be very addressable,' says Mizuho
10/13/21 H.C. Wainwright
Revance price target lowered to $26 from $35 at H.C. Wainwright
10/12/21 William Blair
Revance likely already responded to FDA plant observations, says William Blair
09/15/21 Piper Sandler
Doctor survey favorable for Revance facial injectables, says Piper Sandler
RVNC Revance
$22.72 /

+0.24 (+1.07%)

RVNC Revance
$22.72 /

+0.24 (+1.07%)

Hot Stocks
Femsa CEO Eduardo Padilla to retire, Daniel Rodriguez Cofre to succeed » 17:11
10/15/21
10/15
17:11
10/15/21
17:11
FMX

Femsa

$84.16 /

+0.31 (+0.37%)

Femsa announced that in…

Femsa announced that in accordance with its senior leadership succession planning process, and consistent with previously established timeframes, Eduardo Padilla will retire from his position as Femsa's CEO on January 1, 2022. Accordingly, Femsa's Board of Directors has appointed Daniel Rodriguez Cofre, currently CEO of Femsa Comercio, to become Femsa's CEO as of January 1, 2022. Daniel Rodriguez Cofre joined Femsa in 2015 as Chief Corporate Officer and, since January of 2016, he has been CEO of Femsa Comercio. Prior to Femsa, Daniel occupied several senior finance positions at Shell, and he was CFO and CEO at Cencosud.

ShowHide Related Items >><<
FMX Femsa
$84.16 /

+0.31 (+0.37%)

FMX Femsa
$84.16 /

+0.31 (+0.37%)

08/13/21
Fly Intel: Top five analyst initiations
08/13/21 Goldman Sachs
Femsa initiated with a Buy at Goldman Sachs
08/03/21 Barclays
Femsa price target raised to $90 from $80 at Barclays
08/03/21 Barclays
Femsa price target raised to $90 from $80 at Barclays
FMX Femsa
$84.16 /

+0.31 (+0.37%)

Hot Stocks
Amazon.com supports DOJ's prosecution of four defendant charged with fraud » 17:06
10/15/21
10/15
17:06
10/15/21
17:06
AMZN

Amazon.com

$3,409.08 /

+110.11 (+3.34%)

The United States…

The United States Attorney's Office for the Western District of Michigan charged four individuals in a more than 30 count indictment for their role in defrauding Amazon's textbook rental program. The charges include mail fraud, wire fraud, and making false statements. Amazon's robust anti-fraud systems discovered this scheme and it supported the multi-year investigation. Amazon stated, "Only through close collaboration with law enforcement is the prosecution of fraud like this possible. We are grateful to the United States Attorney's Office for the Western District of Michigan, the Federal Bureau of Investigation, and the U.S. Postal Inspector of Michigan in their thorough pursuit of this case. Fraud undermines the trust of our customers, and jeopardizes the value and selection that entrepreneurs, authors, and publishers provide to millions of customers through our stores. We will continue to pursue all available measures to protect our customers and hold bad actors accountable."

ShowHide Related Items >><<
AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

10/13/21 Baird
Amazon.com weakness would be a buying opportunity, says Baird
10/12/21 JPMorgan
JPMorgan says Alphabet 'clearly the most liked' mega-cap internet stock
10/11/21 Loop Capital
Bed Bath & Beyond price target lowered to $14 from $18 at Loop Capital
10/07/21 Stephens
Comcast-branded Smart TV Launch in U.S. 'likely imminent,' says Stephens
AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

Hot Stocks
General Dynamics awarded $269.49M Navy contract modification » 17:06
10/15/21
10/15
17:06
10/15/21
17:06
GD

General Dynamics

$207.92 /

+2.78 (+1.36%)

General Dynamics was…

General Dynamics was awarded a $269.49M cost-plus-fixed-fee modification to previously awarded contract for lead yard support and development studies and design efforts related to Virginia-class submarines. Work is expected to be completed by October 16. FY21 research, development, test, and evaluation funds in the amount of $13M will be obligated at time of award and will expire at the end of the current fiscal year. This contract was not competitively procured. The statutory authority for this sole source award is in accordance with Defense Federal Acquisition Regulation 6.302-1- only one responsible source and no other supplies or services will satisfy agency requirements. The Naval Sea Systems Command is the contracting activity.

ShowHide Related Items >><<
GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

09/23/21
Fly Intel: Top five analyst upgrades
09/23/21 Goldman Sachs
General Dynamics upgraded to Neutral from Sell at Goldman Sachs
09/21/21 Morgan Stanley
New AUKUS pact could benefit General Dynamics, Raytheon, says Morgan Stanley
07/29/21 Credit Suisse
General Dynamics price target raised to $198 from $182 at Credit Suisse
GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

Hot Stocks
Hertz intends to apply to list its common stock on Nasdaq » 17:02
10/15/21
10/15
17:02
10/15/21
17:02
HTZZ

Hertz

$25.70 /

-0.979 (-3.67%)

Hertz's common stock…

Hertz's common stock currently trades on the over-the-counter market under the symbol "HTZZ". Hertz intends to apply to list its common stock on the Nasdaq Global Select Market under the symbol "HTZ".

ShowHide Related Items >><<
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

07/07/21 Deutsche Bank
Hertz price target raised to $18 from $2 at Deutsche Bank
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

General news
Treasury Market Summary » 17:00
10/15/21
10/15
17:00
10/15/21
17:00
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: risk appetite continued to improve on the heels of strong bank earnings and a better than expected retail sales data. Goldman Sachs' knock Q3 performance added to the stellar reports through the week and an upward surprise in sales eased worries over slowing growth. The Dow was over 1% firmer in late action to lead the rally, thanks in large part to Goldman. The S&P 500 was 0.75% higher, and the NASDAQ was up 0.5%. The demand for stocks left bonds out in the cold and yields ballooned higher, paced by the belly as expectations for Fed liftoff around Q3 2022 continue to rise. The 5-year yield was over 7 bps cheaper at 1.122% into the close. The 10-year rose over 6 bps to 1.575%. The 2-year climbed a steep 4 bps to hit 0.40%, with a 4-handle not seen since March 19, 2020. A heavy data slate included the aforementioned retail sales, a slip in the Empire State manufacturing index, slight erosion in consumer sentiment, and rising trade prices.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Hertz files to sell common stock for holders, no amount given » 16:59
10/15/21
10/15
16:59
10/15/21
16:59
HTZZ

Hertz

$25.70 /

-0.979 (-3.67%)

The offering is expected…

The offering is expected to be commenced in the fourth quarter, subject to market conditions and completion of any regulatory review. Hertz's common stock currently trades on the over-the-counter market under the symbol "HTZZ". Hertz intends to apply to list its common stock on the Nasdaq Global Select Market under the symbol "HTZ" in connection with the offering. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as lead-bookrunning managers for the proposed offering. Barclays Capital Inc. and Deutsche Bank Securities Inc. are acting as additional bookrunners.

ShowHide Related Items >><<
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

07/07/21 Deutsche Bank
Hertz price target raised to $18 from $2 at Deutsche Bank
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

Syndicate
Gritstone files to sell 5M shares of common stock for holders  16:55
10/15/21
10/15
16:55
10/15/21
16:55
GRTS

Gritstone

$9.22 /

-0.16 (-1.71%)

 
ShowHide Related Items >><<
GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

Syndicate
Solaris Oilfield files $500M mixed securities shelf  16:49
10/15/21
10/15
16:49
10/15/21
16:49
SOI

Solaris Oilfield

$8.22 /

+0.05 (+0.61%)

 
ShowHide Related Items >><<
SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

04/09/21 Cowen
Solaris Oilfield downgraded to Market Perform from Outperform at Cowen
02/25/21 B. Riley
Solaris Oilfield price target raised to $14 from $12.50 at B. Riley Securities
01/25/21 B. Riley
Solaris Oilfield price target raised to $12.50 from $11 at B. Riley Securities
12/15/20 Citi
Solaris Oilfield price target raised to $9.60 from $7 at Citi
SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

Hot Stocks
Medtronic provides update on SPYRAL HTN-ON MED clinical study » 16:46
10/15/21
10/15
16:46
10/15/21
16:46
MDT

Medtronic

$127.65 /

+2.86 (+2.29%)

Medtronic is providing an…

Medtronic is providing an update on its SPYRAL HTN-ON MED clinical study of its Symplicity Renal Denervation System to lower blood pressure in typical hypertensive patients taking up to three anti-hypertensive medications. On September 10, the company announced that it was expecting a prespecified interim data analysis of its ON MED study in October. The company is announcing today that it has received notification from its ON MED study independent data safety monitoring board that it has conducted the prespecified interim data analysis and has recommended that clinical trial enrollment continue as planned, until the full, predefined sample size is reached. A prespecified interim analysis is designed to enable early stoppage of clinical trial enrollment should the results be significantly better than the planned clinical trial design assumptions. The trial was designed to follow 260 randomized patients for 6 months post procedure and is powered to detect a statistically significant and clinically relevant therapeutic benefit at the final analysis. The company estimates that the follow-up of the full cohort of patients will be complete in the second half of calendar year 2022. The statistically significant results from the company's three previous sham-controlled SPYRAL studies, and the data from the company's Global Symplicity Registry of more than 3,000 real-world patients, give the company confidence in its renal denervation program, including ultimate approval of the therapy. These data, in addition to the full clinical cohort, will complete the company's robust premarket application to the U.S. FDA. The company expects renal denervation to become a multi-billion dollar market, with global market revenue now expected to exceed $500M by calendar year 2026 and $2-$3B by calendar year 2030. Of note, this update does not impact the company's fiscal year 2022 revenue and EPS guidance, nor does it affect the company's long-range plan to deliver 5%+ organic revenue growth and 8%+ adjusted EPS growth. Management remains confident in its outlook and its pipeline, including its renal denervation program.

ShowHide Related Items >><<
MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

Syndicate
Kore Group files to sell 22.5M shares of common stock for holders  16:37
10/15/21
10/15
16:37
10/15/21
16:37
KORE

Kore Group

$6.82 /

-0.445 (-6.13%)

 
ShowHide Related Items >><<
KORE Kore Group
$6.82 /

-0.445 (-6.13%)

KORE Kore Group
$6.82 /

-0.445 (-6.13%)

10/11/21 Cowen
Kore Group initiated with an Outperform at Cowen
10/01/21 LightShed Partners
Kore Group initiated with a Buy at LightShed Partners
08/16/21 Northland
Cerberus Telecom Acquisition initiated with an Outperform at Northland
Conference/Events
Accuray to hold analyst & investor meeting » 16:36
10/15/21
10/15
16:36
10/15/21
16:36
ARAY

Accuray

$3.94 /

+0.03 (+0.77%)

Analyst & Investor…

Analyst & Investor Meeting being held in conjunction with the ASTRO Annual Meeting on October 25 at 4 pm. Webcast Link

ShowHide Related Items >><<
ARAY Accuray
$3.94 /

+0.03 (+0.77%)

ARAY Accuray
$3.94 /

+0.03 (+0.77%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Northland
Accuray initiated with an Outperform at Northland
ARAY Accuray
$3.94 /

+0.03 (+0.77%)

Syndicate
Murphy Oil files automatic mixed securities shelf  16:35
10/15/21
10/15
16:35
10/15/21
16:35
MUR

Murphy Oil

$28.52 /

-0.16 (-0.56%)

 
ShowHide Related Items >><<
MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

10/07/21 Truist
Murphy Oil price target raised to $40 from $37 at Truist
07/15/21 Mizuho
Murphy Oil price target raised to $28 from $24 at Mizuho
07/01/21 Truist
Murphy Oil price target raised to $36 from $24 at Truist
05/17/21 Mizuho
Murphy Oil price target raised to $24 from $21 at Mizuho
MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

On The Fly
Short Interest Report: New York Times shorts squeezed by breakout » 16:33
10/15/21
10/15
16:33
10/15/21
16:33
BGFV

Big 5 Sporting

$23.95 /

-0.06 (-0.25%)

, FUV

Arcimoto

$10.33 /

-0.17 (-1.62%)

, LXU

LSB Industries

$9.25 /

-0.315 (-3.29%)

, MSTR

MicroStrategy

$750.46 /

+24.31 (+3.35%)

, PHAS

PhaseBio

$3.98 /

-0.02 (-0.50%)

, BOLT

Bolt Biotherapeutics

$13.52 /

-0.03 (-0.22%)

, NYT

New York Times

$53.15 /

-1.16 (-2.14%)

, SDC

SmileDirectClub

$5.53 /

-0.21 (-3.66%)

Welcome to this week’s…

ShowHide Related Items >><<
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

08/04/21 Lake Street
Big 5 Sporting price target raised to $31 from $26 at Lake Street
05/05/21 Lake Street
Big 5 Sporting price target raised to $26 from $19 at Lake Street
03/03/21 Lake Street
Big 5 Sporting price target raised to $19 from $16 at Lake Street
01/14/21 Lake Street
Lake Street bumps Big 5 Sporting price target to $16 after Q4 pre-announcement
FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

09/10/21
Fly Intel: Top five analyst initiations
09/10/21 Alliance Global Partners
Arcimoto initiated with a Buy at Alliance Global Partners
04/01/21
Fly Intel: Top five analyst downgrades
04/01/21 H.C. Wainwright
Arcimoto downgraded to Neutral from Buy at H.C. Wainwright
LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

08/24/21 Jefferies
MicroStrategy price target raised to $700 from $640 at Jefferies
08/20/21 Citi
Citi places Sell rating on MicroStrategy under review over bitcoin
07/30/21 Canaccord
MicroStrategy price target lowered to $780 from $920 at Canaccord
07/30/21 BTIG
MicroStrategy price target raised to $950 from $850 at BTIG
PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

10/13/21 Stifel
PhaseBio resumed with a Buy at Stifel
05/14/21 William Blair
PhaseBio remains 'significantly undervalued,' says William Blair
03/16/21 Needham
PhaseBio price target raised to Street high $19 at Needham
BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
NYT New York Times
$53.15 /

-1.16 (-2.14%)

05/06/21 JPMorgan
New York Times shares may be range-bound near term, says JPMorgan
03/18/21 Guggenheim
Guggenheim upgrades News Corp. to Buy, sees 'significant value' to be unlocked
11/09/20 Evercore ISI
New York Times upgraded to Outperform from In Line at Evercore ISI
10/27/20 JPMorgan
New York Times selloff brings attractive entry point, says JPMorgan
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

09/30/21 Credit Suisse
SmileDirectClub assumed with an Outperform at Credit Suisse
09/20/21 Stifel
Stifel cuts SmileDirectClub to Hold on market share loss, growth uncertainty
09/20/21 Stifel
SmileDirectClub downgraded to Hold from Buy at Stifel
08/13/21
Fly Intel: Top five analyst downgrades
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

  • 18
    Mar
  • 05
    Feb
  • 24
    Nov
  • 19
    Nov
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.